Proteus Vulgaris: Infections, Causes, and Treatment

Proteus vulgaris is a gram-negative bacterium best known for causing urinary tract infections, wound infections, and occasionally bloodstream infections, particularly in people with weakened immune systems or indwelling medical devices like urinary catheters. It belongs to the Enterobacteriaceae family alongside better-known pathogens like E. coli and Klebsiella, and while its close relative Proteus mirabilis gets more clinical attention, P. vulgaris carries its own set of virulence tools and a growing resistance profile that makes it a genuine concern in healthcare settings.

Where Proteus Vulgaris Lives and How It Spreads

Proteus species, including P. vulgaris, are low-abundance commensals of the human gut, meaning they live in your intestines in small numbers without necessarily causing harm.¹ The intestines of humans and animals are considered the primary reservoir. Many wild and domestic animals also carry Proteus bacteria as parasites or commensals, and when these organisms end up in soil or water, their presence often signals fecal contamination.² Contaminated water or seafood can pose a risk, especially when drug-resistant strains from animal or human intestines make their way into the environment.

In hospitals and long-term care facilities, the transmission picture shifts. Proteus infections frequently arise when the bacterium migrates from the gut or perineal skin to the urinary tract, particularly along the surface of a catheter. This is not a disease you “catch” from another person in the way you might catch a cold. Instead, your own gut flora or environmental exposure gives the organism a foothold, and circumstances like catheterization, surgery, or immune suppression give it an opportunity to cause trouble.

What Makes It Dangerous

P. vulgaris has several biological features that help it establish infection and resist your body’s defenses. Understanding these helps explain why Proteus infections tend to be stubborn and why they frequently involve complications like kidney stones.

Urease and Stone Formation

The single most clinically important weapon in the Proteus arsenal is urease, an enzyme that breaks down urea into ammonia. This reaction raises the pH of urine, making it more alkaline. In that alkaline environment, minerals like magnesium ammonium phosphate and calcium phosphate crystallize out of solution, forming what clinicians call struvite or infection stones.³ These stones can grow rapidly, sometimes filling an entire kidney (a condition called a staghorn calculus). A study of Proteus isolates from diabetic foot infections and urinary tract infections found the urease gene (ureA) in 100% of UTI isolates, confirming that virtually every Proteus strain capable of infecting the urinary tract carries this gene.⁴

Swarming Motility

If you have ever seen a Proteus culture in a microbiology lab, you may have noticed something unusual: the bacteria spread outward in concentric rings rather than staying put in a neat colony. This swarming behavior involves individual cells elongating dramatically and growing extra flagella, which lets them glide across surfaces in coordinated waves. On catheter tubing or tissue surfaces, swarming helps the organism colonize territory quickly and move upstream into the urinary tract toward the kidneys.

Biofilm Formation

Proteus species are skilled biofilm builders. In urinary catheters, P. mirabilis and P. vulgaris form crystalline biofilms that incorporate mineral deposits from the alkaline urine their urease creates. These biofilms are notoriously hard to treat because antibiotics struggle to penetrate the matrix, and the bacteria inside are metabolically less active, making them less vulnerable to drugs that target dividing cells. In P. mirabilis specifically, researchers have identified adhesion proteins, quorum-sensing molecules, lipopolysaccharides, and efflux pumps as key ingredients in biofilm construction.⁵ P. vulgaris shares many of these tools and uses similar strategies to establish itself on catheter surfaces and in wound beds.

Types of Infections

Although Proteus mirabilis accounts for the majority of clinical Proteus infections, P. vulgaris plays a distinct role that tends to surface in particular patient populations and body sites.

Urinary Tract Infections

UTIs are the bread and butter of Proteus pathology. The typical scenario involves a hospitalized or catheterized patient who develops symptoms ranging from painful urination and foul-smelling urine to fever, flank pain, and signs of kidney involvement. Proteus UTIs are disproportionately associated with complicated infections, meaning they occur in people with abnormal urinary tracts, catheters, or underlying conditions like diabetes. The alkaline urine and stone formation described earlier can turn a straightforward bladder infection into a chronic, recurrent problem that resists standard treatment. When stones form, bacteria can hide inside them, re-seeding the infection after antibiotics are stopped.

Wound and Diabetic Foot Infections

P. vulgaris also appears in wound cultures, particularly in diabetic foot ulcers. In one study examining Proteus isolates from clinical samples, 46 out of 78 isolates came from wound cultures rather than urine, and 21 of those 78 total isolates were identified as P. vulgaris specifically.⁴ Diabetic foot infections are often polymicrobial, meaning multiple bacterial species are present simultaneously, and Proteus tends to be one player in a mixed community rather than the sole culprit. Its proteolytic enzymes, which break down proteins, contribute to tissue destruction in these wounds.

Bloodstream Infections

When Proteus escapes the urinary tract or a wound and enters the bloodstream, the consequences can be severe. Bacteremia caused by Proteus species carries a 14-day mortality rate of roughly 29% in elderly patients, with secondary bacteremia most commonly originating from the urinary tract.⁶ That figure is sobering and underscores why Proteus UTIs in older or immunocompromised patients need to be taken seriously before they progress.

Ear Infections and Other Sites

P. vulgaris occasionally turns up in chronic suppurative otitis media, a persistent draining ear infection. In a study of bacterial agents causing this condition, P. vulgaris was among the organisms isolated, though at lower rates (under 2% of isolates) compared to Staphylococcus aureus and Pseudomonas aeruginosa, which dominated.⁷ Proteus species have also been reported in respiratory tract infections, intra-abdominal infections, and neonatal sepsis, though these are less common than the urinary and wound presentations.

Who Is Most at Risk

You are unlikely to develop a P. vulgaris infection if you are generally healthy and not hospitalized. The people who face the highest risk share a few common profiles:

Catheterized patients: Long-term urinary catheters are the single biggest risk factor. The longer the catheter stays in, the higher the chance of colonization and subsequent infection.
Elderly individuals: Older adults in hospitals and nursing homes have both higher colonization rates and worse outcomes when infection develops, as reflected in the high mortality figures for Proteus bacteremia in this group.
People with diabetes: Diabetes impairs immune function and blood flow, especially to the extremities, making diabetic foot ulcers a common entry point for P. vulgaris.
Immunocompromised patients: Anyone with a weakened immune system from chemotherapy, organ transplant medications, or HIV is more vulnerable to opportunistic infections from gut commensals like Proteus.
Patients with urinary tract abnormalities: Structural problems in the urinary tract, including kidney stones from a previous Proteus infection, create niches where bacteria can persist and reinfect.

Antibiotic Resistance and Why It Matters for Treatment

Treating P. vulgaris infections has become increasingly complicated as the bacterium acquires resistance to more antibiotics. All Proteus species are naturally resistant to certain drugs, including colistin and tigecycline, which limits the fallback options that doctors rely on for other tough gram-negative infections.⁸ That intrinsic resistance is a problem because it narrows the toolkit from the start.

On top of the built-in resistance, many P. vulgaris strains have picked up genes for extended-spectrum beta-lactamases (ESBLs), enzymes that chew through penicillins and many cephalosporins. In one hospital study from India, roughly 88% of Proteus isolates tested positive for ESBL production, and over half of those also co-produced AmpC beta-lactamase, another enzyme that defeats a different class of antibiotics.⁹ A systematic review and meta-analysis of Proteus species in urinary tract infections in Iran found resistance to ampicillin at about 72%, piperacillin at 64%, and trimethoprim-sulfamethoxazole at roughly 49%. Multidrug resistance, defined as resistance to three or more antibiotic classes, was present in about 58% of isolates.¹⁰

These numbers vary by region and hospital, but the trend is clearly heading in the wrong direction. The practical takeaway is that empirical antibiotic therapy, where a doctor prescribes based on a best guess before culture results come back, is increasingly unreliable for Proteus infections. Getting a urine or wound culture and waiting for susceptibility results has become essential rather than optional.

Which Antibiotics Still Work

Despite the grim resistance picture, several drug classes remain effective for most Proteus infections. The same Iranian meta-analysis that documented high ampicillin resistance found that levofloxacin retained 100% susceptibility and norfloxacin was effective against about 93% of isolates. Imipenem resistance was present in roughly 15% of strains, meaning carbapenems still work in most cases but cannot be taken for granted.¹⁰ That analysis suggested that beta-lactam/beta-lactamase inhibitor combinations, carbapenems, and fluoroquinolones are currently the most appropriate treatments for Proteus UTIs in that region.

In practice, treatment decisions depend on the infection’s location and severity:

Uncomplicated UTIs: Fluoroquinolones like ciprofloxacin or levofloxacin are commonly used if the local resistance profile supports it. Trimethoprim-sulfamethoxazole may work if the specific isolate is susceptible, but given the nearly 50% resistance rate seen in some populations, it is not a safe blind choice.
Complicated UTIs and pyelonephritis: Broader-spectrum agents like carbapenems (meropenem, imipenem) or piperacillin-tazobactam are typical choices for severe infections, with de-escalation to a narrower drug once culture results arrive.
Bacteremia: Intravenous carbapenems or broad-spectrum cephalosporins guided by susceptibility testing are the standard, often combined with source control such as catheter removal or abscess drainage.
Wound infections: Treatment depends on culture results and whether the infection is polymicrobial. Surgical debridement of dead tissue is often as important as antibiotic choice.

One critical point: if kidney or bladder stones have formed, antibiotics alone will not resolve the infection. Bacteria embedded in struvite stones are shielded from drug penetration, and the stones themselves need to be removed surgically or broken up with procedures like lithotripsy. Treating the infection without addressing the stones is a recipe for relapse.

Proteus Vulgaris Versus Proteus Mirabilis

If you look at clinical microbiology reports, P. mirabilis appears far more often than P. vulgaris. P. mirabilis is the dominant human pathogen in the genus, causing the vast majority of Proteus-related UTIs. P. vulgaris tends to show up in more specific niches, such as wound infections, and is generally considered more resistant to antibiotics out of the gate. One traditional lab distinction is the indole test: P. vulgaris produces indole from the amino acid tryptophan, while P. mirabilis does not. This simple biochemical difference has been a workhorse of clinical microbiology identification for decades.

The taxonomy of P. vulgaris itself has been revised over the years. What was formerly called P. vulgaris biogroup 3 was reclassified as a separate species, Proteus hauseri, while additional unnamed genomospecies were also split off.¹¹ This means that some older studies attributing infections to P. vulgaris may have actually been dealing with these related but distinct organisms. For the patient, this taxonomic fine print rarely changes management, but it does mean that epidemiological data on P. vulgaris from before the 2000s should be interpreted with a grain of salt.

Preventing Proteus Infections

Because the single largest risk factor is catheter use, the most effective prevention strategy is straightforward: avoid urinary catheters when possible, and remove them as soon as they are no longer needed. Hospitals have adopted catheter stewardship programs specifically for this reason, with daily assessments of whether a catheter is still necessary. For patients who require long-term catheterization, regular catheter changes, closed drainage systems, and meticulous hygiene around the catheter site all reduce the risk of Proteus colonization.

For people with recurrent Proteus UTIs complicated by struvite stones, prevention overlaps with treatment. Complete stone removal is essential to eliminate the bacterial reservoir inside the stone. Acidifying the urine through dietary changes or medications can theoretically discourage struvite crystallization, though evidence for this approach is limited and compliance is difficult.

Researchers have also been exploring catheter coatings designed to prevent bacterial adhesion and biofilm formation. One approach using chitosan-zinc oxide coatings showed the ability to decrease bacterial adherence by over four log units (a reduction of more than 99.99%), lower biofilm biomass by 80 to 90%, and prevent mineral deposition caused by P. mirabilis by roughly 67 to 70%, keeping catheters patent for 14 days in laboratory testing.¹² These results are promising but still largely experimental, and widespread clinical adoption has not yet arrived.

The Gut Connection

An emerging area of interest is the role Proteus species play in the gut beyond simple commensalism. Proteus has traditionally been viewed as a harmless intestinal hitchhiker that only causes problems when it ends up somewhere it does not belong, like the urinary tract. But researchers have begun to investigate whether Proteus species may contribute to gastrointestinal inflammation under certain conditions.¹ These bacteria are proteolytic, meaning they aggressively break down proteins, and they harbor significant pathogenic potential even when present in low numbers. Some researchers have proposed links between Proteus overgrowth in the gut and inflammatory bowel conditions, though this work remains preliminary and no causal relationship has been firmly established.

What is better established is that the gut serves as the staging ground for Proteus infections elsewhere in the body. Drug-resistant strains that colonize the intestines can later seed urinary tract or wound infections, and those resistant strains can also enter the environment through fecal contamination of water and soil.² This environmental cycling raises the possibility that antibiotic-resistant Proteus picked up from contaminated food or water could later cause a difficult-to-treat infection, a scenario that has already been documented with other Enterobacteriaceae like E. coli.